Pathology in drug discovery and development

Journal of Pathology

Volumn 232, Issue 2, 2014, Pages 99-102

  Jubb, Adrian M ^a   Koeppen, Hartmut ^a   Reis Filho, Jorge S ^b  

^a GENENTECH INC   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

biomarkers; companion diagnostics; drug development; pathology

Indexed keywords

B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; ONARTUZUMAB; PEMETREXED; RILOTUMUMAB; VASCULOTROPIN INHIBITOR;

ADENOCARCINOMA; CANCER PROGNOSIS; CANCER THERAPY; DIABETIC MACULAR EDEMA; DRUG APPROVAL; DRUG RESEARCH; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LUNG CANCER; MELANOMA; METAMORPHOSIS; NEOPLASM; ONCOLOGY; PATHOLOGIST; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; STOMACH CANCER; TRIPLE NEGATIVE BREAST CANCER; TUMOR BIOPSY; TUMOR IMMUNITY;

BIOMARKERS; COMPANION DIAGNOSTICS; DRUG DEVELOPMENT; PATHOLOGY;

ANIMALS; BIOLOGICAL MARKERS; BIOPSY; DRUG DISCOVERY; FORECASTING; HUMANS; MOLECULAR TARGETED THERAPY; PATHOLOGY;

EID: 84890283024     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4290     Document Type: Review

References (38)

1. Bates J, Diehl L,. Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity? J Pathol 2014; 232: 112-120.
2. Das Thakur M, Pryer NK, Singh M,. Advances in mouse tumour models to guide drug development and identify resistance mechanisms. J Pathol 2014; 232: 103-111.
3. Shames DS, Wistuba II,. The evolving genomic classification of lung cancer. J Pathol 2014; 232: 121-133.
4. Soda M, Takada S, Takeuchi K, et al., A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008; 105: 19893-19897.
5. Koeppen H, Rost S, Yauch RL,. Developing biomarkers to predict benefit from HGF-MET pathway inhibitors. J Pathol 2014; 232: 210-218.
6. Smith NR, Womack C,. A matrix approach to guide IHC-based tissue biomarker development in oncology drug discovery. J Pathol 2014; 232: 190-198.
7. Homet B, Ribas A,. New drug targets in metastatic melanoma. J Pathol 2014; 232: 134-141.
8. Hatzivassiliou G, Song K, Yen I, et al., RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-435.
9. Nagtegaal ID, West NP, van Krieken JHJM, et al., Pathology is a necessary and informative tool in oncology clinical trials. J Pathol 2014; 232: 185-189.
10. Bollag G, Hirth P, Tsai J, et al., Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467: 596-599.
11. Scagliotti GV, Parikh P, von Pawel J, et al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
12. Johnson DH, Fehrenbacher L, Novotny WF, et al., Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
13. Gianni L, Pienkowski T, Im YH, et al., Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
14. Prowell TM, Pazdur R,. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012; 366: 2438-2441.
15. Groenen PJ, Blokx WA, Diepenbroek C, et al., Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. Histopathology 2011; 59: 1-7.
16. Simeon-Dubach D, Burt AD, Hall PA,. Quality really matters: the need to improve specimen quality in biomedical research. J Pathol 2012; 228: 431-433.
17. van Lookeren Campagne M, LeCouter J, Yaspan BL, et al., Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol 2014; 232: 151-164.
18. Chen DS, Mellman I,. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39: 1-10.
19. Topalian SL, Hodi FS, Brahmer JR, et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
20. Hamid O, Robert C, Daud A, et al., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
21. Wolchok JD, Kluger H, Callahan MK, et al., Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
22. Galon J, Mlecnik B, Bindea G, et al., Towards the introduction of the Immunoscore in the classification of malignant tumours. J Pathol 2014; 232: 199-209.
23. Montemurro F, Scaltriti M,. Biomarkers of drugs targeting HER-family signalling in cancer. J Pathol 2014; 232: 219-229.
24. Lehmann BD, Pietenpol JA,. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 2014; 232: 142-150.
25. Olar A, Aldape KD,. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 2014; 232: 165-177.
26. Rodrigues DN, Butler LM, Llorente D, et al., Molecular pathology and prostate cancer therapeutics: from biology to bedside. J Pathol 2014; 232: 178-184.
27. Smith SA, French T, Hollingsworth SJ,. The impact of germline mutations on targeted therapy. J Pathol 2014; 232: 230-243.
28. Schilsky RL, Doroshow JH, Leblanc M, et al., Development and use of integral assays in clinical trials. Clin Cancer Res 2012; 18: 1540-1546.
29. Sequist LV, Heist RS, Shaw AT, et al., Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011; 22: 2616-2624.
30. Eisenstein M., Foundation medicine. Nat Biotechnol 2012; 30: 14.
31. Wagle N, Berger MF, Davis MJ, et al., High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012; 2: 82-93.
32. Flaherty KT, Infante JR, Daud A, et al., Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
33. Blair BG, Bardelli A, Park BH,. Somatic alterations as the basis for resistance to targeted therapies. J Pathol 2014; 232: 244-254.
34. Weigelt B, Reis-Filho JS,. Epistatic interactions and drug response. J Pathol 2014; 232: 255-263.
35. Arnedos M, Viehl P, Soria JC, et al., The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? J Pathol 2014; 232: 274-282.
36. Crockford A, Jamal-Hanjani M, Hicks J, et al., Implications of intratumour heterogeneity for treatment stratification. J Pathol 2014; 232: 264-273.
37. Vakoc BJ, Fukumura D, Jain RK, et al., Cancer imaging by optical coherence tomography: preclinical progress and clinical potential. Nat Rev Cancer 2012; 12: 363-368.
38. Misale S, Yaeger R, Hobor S, et al., Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-536.